BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation https://ir.ataibeckley.com/news-rel...ates-rapid-and-durable-antidepressant-effects A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression https://journals.sagepub.com/doi/10.1177/02698811261420087
BPL-003 Nasal Spray Shows Quick and Enduring Effect in Treatment-Resistant Depression https://www.psychiatrictimes.com/vi...ring-effect-in-treatment-resistant-depression
Ukraine's Other Battle: Healing the Invisible Wounds of War Ukraine's therapists seek ways to fund trials of psychedelics despite huge hurdles. https://www.psychologytoday.com/us/...er-battle-healing-the-invisible-wounds-of-war
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst https://ir.ataibeckley.com/news-rel...-trillion-crsp-index-and-sp-benchmark-indices
GOP Senator To File Bill Promoting Psychedelics Research And Treatment For Veterans https://www.marijuanamoment.net/gop...hedelics-research-and-treatment-for-veterans/
Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003? https://finance.yahoo.com/sectors/h...ibeckley-inc-atai-looking-sell-181120202.html
Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants https://www.science.org/doi/10.1126/sciadv.aeb3034 This paper is not about discovering new psychedelics. It is about controlling how they are made. The researchers produced DMT, psilocin, psilocybin, bufotenin, and 5-MeO-DMT in a plant system by rebuilding the full biosynthetic pathway. The implication is on the production side, which is where this becomes relevant for companies like $DFTX, $ATAI, and $CMPS if they are positioned anywhere along the supply or formulation chain. A lot of these compounds today still rely on complex synthesis or extraction workflows. This approach shifts production toward programmable biosynthesis. That means more consistent batches, tighter purity control, and likely a lower cost per gram at scale. As these companies move through FDA pathways, manufacturing becomes critical. Cost of goods and consistency directly impact margins, scalability, and pricing. It is not just about proving the therapy works. It is about producing it reliably at pharmaceutical grade. The takeaway here is infrastructure. Lower production costs, better control, and more flexibility in compound design all strengthen the long term commercial case for companies working to bring these therapies to market.
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs https://ir.ataibeckley.com/news-rel...3-shows-rapid-durable-antidepressant-response 66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts Durable responses observed at Day 85: 83% (5/6) (10 mg) and 66.7% (4/6) (12 mg) BPL-003 received FDA Breakthrough Therapy Designation in October 2025 Phase 3 initiation on track for Q2 2026 https://clinicaltrials.gov/study/NCT05660642 https://link.springer.com/article/10.1007/s40263-025-01250-z
From Toad "Venom" to Potential Antidepressant https://www.psychologytoday.com/us/...4/from-toad-venom-to-potential-antidepressant
Psychedelics Executive Order — News Coverage Roundup The Washington Post Trump orders more access to psychedelics like LSD, psilocybin and ibogaine https://www.washingtonpost.com/politics/2026/04/17/trump-psychedelics-psylocibin-research/ Pittsburgh Post-Gazette Trump signs order to speed review of psychedelics, including the controversial drug ibogaine https://www.post-gazette.com/news/p...-drugs-ibogaine-veterans/stories/202604180045 WSAZ President Trump signs executive order encouraging research on psychedelic drugs https://www.wsaz.com/2026/04/18/pre...order-encouraging-research-psychedelic-drugs/ CNN Trump accelerates research on psychedelic treatments and asks, ‘Can I have some?’ https://www.cnn.com/2026/04/18/poli...rging-more-research-into-psychedelic-ibogaine MS NOW Trump signs executive order on psychedelic drugs — with Joe Rogan by his side https://www.ms.now/news/trump-executive-order-psychedelic-drugs-joe-rogan The Guardian Trump announces reforms to accelerate access to psychedelic drug treatments https://www.theguardian.com/us-news/2026/apr/18/trump-psychedelic-drugs-executive-order USA Today Trump signs order pushing psychedelics research after Joe Rogan call https://www.usatoday.com/story/news...ive-order-psychedelics-joe-rogan/89676816007/ Reuters Trump signs order to accelerate access to psychedelic drug treatments https://www.reuters.com/world/trump...ccess-psychedelic-drug-treatments-2026-04-18/ Bloomberg Trump Signs Order on Psychedelics to Ease FDA Restrictions https://www.bloomberg.com/news/arti...rder-easing-restrictions-on-psychedelic-drugs The Wall Street Journal How Joe Rogan Convinced Trump to Fast-Track Review of Psychedelic Drugs https://www.wsj.com/politics/policy...st-track-review-of-psychedelic-drugs-3618fd73
ABC News - Trump signs executive order to accelerate research of psychedelic-based drugs Interview with Martin MaKary
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder April 22, 2026 PDF Version EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points (p=0.004) on SAFE - a 38% and 32% reduction, respectively Patient-perceived global improvement: 49% PGI-C responders at Day 43 compared to 12% on placebo No severe or serious adverse events https://ir.ataibeckley.com/news-rel...ces-additional-phase-2a-results-emp-01-oral-r
Apeiron’s Christian Angermayer on using psychedelic drugs for mental health treatment https://www.cnbc.com/video/2026/04/...t.html?__source=sharebar|twitter&par=sharebar
$ATAI DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD) https://www.businesswire.com/news/h...for-the-Treatment-of-Alcohol-Use-Disorder-AUD this should bode well for ATAI
PANEL: Clinical Risk, Regulatory Reality and the Path to Scale - Needham Virtual Psychedelics Forum $DFTX $ATAI $CMPS https://event.summitcast.com/view/H.../guest_book?session_id=nXqi2QwF47Ftq7xFM8Bt5j
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update https://ir.ataibeckley.com/news-rel...orts-first-quarter-2026-financial-results-and Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029
Americans are increasingly open to using psychedelics for medical reasons https://www.scientificamerican.com/...en-to-using-psychedelics-for-medical-reasons/
Is this finally the breakthrough moment for psychedelic therapies? https://www.rbccm.com/en/insights/2...breakthrough-moment-for-psychedelic-therapies Psychedelics may finally be close to mainstream medical use, but is the healthcare system prepared for mass delivery to patients? Hosted By Joseph Coletti Featuring Brian Abrahams and Leonid Timashev Published May 22, 2026 Key points Patient and physician interest and favorable regulation signal an imminent breakthrough for psychedelics to treat mental ill-health. April’s Presidential order on accelerated research and access for veterans with PTSD is also supportive. Psychedelics raise challenges for clinical trials, but companies are finding ways to overcome these. RBC’s research indicates existing clinic infrastructure is equipped to deliver psychedelics with the required clinical supervision.
Where Psychedelic Treatments Fit in Modern Clinical Care PAT as specialty care, not a replacement for ongoing therapies. https://www.psychologytoday.com/us/blog/modern-medicine/202605/where-psychedelic-treatments-fit-in-modern-clinical-care Key points PAT may be best understood as a specialty mental health intervention embedded in collaborative care. Referral pathways mirror a familiar primary-care-to-specialist model used across medicine and psychology. PAT can help patients become more emotionally flexible and engaged in ongoing therapy. Ideal integration depends on continuity, communication, and returning patients to their primary providers.
Why Trump is pushing psychedelics research to treat mental illness https://www.cnbc.com/video/2026/05/...edelics-research-to-treat-mental-illness.html
